Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer
暂无分享,去创建一个
W. Chan | E. Haura | A. Beg | Z. Thompson | Dung-Tsa Chen | J. Gray | A. Chiappori | B. Creelan | T. Rose | A. Saltos | R. Thapa | Dung-tsa Chen
[1] G. Molina,et al. Mixed Response to Immunotherapy in Patients with Metastatic Melanoma , 2020, Annals of Surgical Oncology.
[2] Ash A. Alizadeh,et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer , 2020, JAMA oncology.
[3] Jae Cheol Lee,et al. Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors , 2020, Oncoimmunology.
[4] S. Vinod,et al. Oligometastatic Disease in NSCLC - Not Just Wishful Thinking? , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] Y. Shimada. Accelerating the development of therapeutic strategy for oligometastasis. , 2019, Journal of thoracic disease.
[6] B. Rubio-Viqueira,et al. Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions , 2019, World journal of clinical oncology.
[7] Michael Lock,et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial , 2019, The Lancet.
[8] J. Lee,et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Y. Ohe,et al. Mixed response to osimertinib and the beneficial effects of additional local therapy , 2019, Thoracic cancer.
[10] D. Planchard,et al. Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy , 2018, JAMA oncology.
[11] R. Tabatabai,et al. Immunotherapy and Mixed Radiographic Response in Non-Small Cell Lung Cancer , 2018 .
[12] M. Nishino. Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[13] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Wolchok,et al. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] James R. Anderson,et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Goetghebeur,et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Camidge,et al. Reviewing RECIST in the Era of Prolonged and Targeted Therapy. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[18] E. Felip,et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Hauschild,et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] E. Giovannetti,et al. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib , 2017, OncoTargets and therapy.
[21] Young Hak Kim,et al. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study , 2017, ESMO Open.
[22] F. Hodi,et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.
[23] P. V. van Laar,et al. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis , 2017, Clinical Neuroradiology.
[24] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[25] Henry Knipe,et al. Oligometastases , 2016, Radiopaedia.org.
[26] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[27] K. Harrington,et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.
[28] Michael Thomas,et al. Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial , 2016, The Lancet. Oncology.
[29] G. Scagliotti,et al. Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK‐rearranged (ALK+) non‐small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND‐1 and ASCEND‐2 trials: 141PD , 2016, Journal of Thoracic Oncology.
[30] M. Ahn,et al. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. , 2016, JAMA oncology.
[31] D. Sargent,et al. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. , 2015, Journal of the National Cancer Institute.
[32] D. Sargent,et al. Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[34] Roman K. Thomas,et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[36] R. Sinha,et al. Joint modeling tumor burden and time to event data in oncology trials , 2014, Pharmaceutical statistics.
[37] Liang Shen,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[38] A. Hoos,et al. Adaptation and modification of the immune related response criteria (IRRC): IrRECIST. , 2014 .
[39] T. Goto,et al. Combination chemotherapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II single arm clinical trial. , 2014 .
[40] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[41] D. Sargent,et al. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] A. Adjei,et al. Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[43] M. A. van den Bosch,et al. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases. , 2013, European Journal of Cancer.
[44] T. Mok,et al. EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. , 2012, The oncologist.
[45] Dung-Tsa Chen,et al. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. , 2011, Journal of the National Cancer Institute.
[46] G. Sica,et al. Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study. , 2011, Journal of Clinical Oncology.
[47] S. Antoniu. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? , 2011, Expert opinion on therapeutic targets.
[48] T. Shukuya,et al. Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. , 2010, Anticancer research.
[49] P. Hohenberger,et al. Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. , 2010 .
[50] S. Ramalingam,et al. Paclitaxel for non-small cell lung cancer , 2004, Expert opinion on pharmacotherapy.
[51] P. Iyengar,et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.
[52] Yi-long Wu,et al. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer. , 2017, The oncologist.
[53] Seth M. Cohen,et al. Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.